Clinical Trial Update: Ramucirumab Plus FOLFIRI Versus Ramucirumab Plus Paclitaxel in Patients With Advanced or Metastatic Gastric Cancer, Who Failed One Prior Line of Palliative Chemotherapy [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 trial comparing ramucirumab plus FOLFIRI versus ramucirumab plus paclitaxel in patients with advanced or metastatic gastric/EGJ cancer after one pri…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophagogastric Junction Cancer
• Gastric Cancer

Drugs mentioned

• FOLFIRI regimen (irinotecan + leucovorin + 5-fluorouracil)
• PACLITAXEL (PACLITAXEL)
• Ramucirumab (ramucirumab)

Snippet

Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Conditions: Advanced Gastric or EGJ Cancer | Phase 2, Phase 3 | Status: ACTIVE_NOT_RECRUITING